本文来自云健康
美国芝加哥消息－ 近日来自于世界各地的 3 万 8000临床肿瘤医生和国际药企汇集美国芝加哥，参加美国临床肿瘤学会（ASCO）第 52 届学术年会。在本次的国际性学术盛会上，位于美国硅谷的 Predicine 公司和云健康基因科技（上海）有限公司今天联合宣布为中国的肺癌患者和前列腺癌患者提供基于血液的无创伤癌症检测服务。
在中国，肺癌已成为疾病死因之首。前列腺癌目前是在中国发病率增长最快的恶性肿瘤，也是西方男性最常见和死亡率排名第二的常见肿瘤。今年早时在美国旧金山举办的国际分子医学第23届学术年会上，Predicine 公司总裁 Winston Patrick Kuo 博士宣布了“PrediSeq－肺癌”二代测序液态活检产品。今年4月，在美国新奥尔良举办的美国癌症研究学会（AACR）第 107 届学术年会上，Predicine 公司发布了世界首款针对前列腺癌症的“PrediSeq－前列腺癌” 二代测序液态活检产品。这两项产品都是基于 Predicine 的液态活检专利技术通过检测血液中游离核酸的基因变异（点突变、拷贝数变异、插入\缺失、重排和剪接变异）来指导临床治疗方案、监控用药疗效、和鉴定潜在抗药性的发病机制。
“我们的愿景是精准衔接患者和医疗，我们的使命是通过科技创新来促进全球的健康产业系统。在无创伤癌症检测、精准医疗和新药开发方面，我们坚持对原创性科研和技术创新的强力投入，在产品－学术－研发－教育四方面进行全方位的全球布局。”Predicine 公司创始人、董事长兼首席执行官贾士东博士说。“通过与云健康等业界顶尖企业合作，Predicine 在产品研发和临床应用方面与战略合作伙伴实现优势互补、双方能够在最短的时间内将最新的无创伤癌症诊断技术应用于临床治疗”贾士东博士补充说。“在肺癌和前列腺癌之后，我们近期将推出针对中国人常见癌症的无创伤液态活检产品。”
“PrediSeq－肺癌”和“PrediSeq－前列腺癌”液态活检产品经过了严格的技术检测和临床验证，目前已经被多家在美国的全球顶尖制药公司所采用。“国际制药公司对 PrediSeq 的认可是对 Predicine 超一流科研团队和强大科研实力在品牌、技术和产品上的最好背书，”云健康 CEO 兼联合创始人金刚博士在声明中如是表示。“通过与 Predicine 的多方位合作、我们联手在第一时间内为中国癌症病人提供世界领先的分子诊断从而实现精准治疗”金博士补充道。
关于 Predicine
Predicine 是一家专注于精准诊断、精准治疗和大数据分析的国际化精准医疗组织。Predicine 的成员来自于世界顶尖企业的资深专家和学者，在临床肿瘤学、液态活检、癌症诊断、二代测序、生物标记物开发、药物研发、临床药物试验、生物信息学和大数据云计算等方面处在业界领先地位。坚持“科研驱动”和“患者为中心”的原则，Predicine 开发针对癌症及其他重要疾病的无创伤液态活检产品、提供“一站式”生物标志物服务平台、进行大数据云计算分析，致力于推动临床精准诊疗和全球*药性**物开发。公司位于美国硅谷和中国上海。更多信息请浏览 www.predicine.com。
关于云健康
云健康是一家专注精准医学转化应用的基因组学高科技公司，是中国精准医疗高通量测序的领先者和倡导者之一。获国家发改委首批基因检测示范中心，中国自贸区国际精准医疗合作中心。
云健康建立了全球最先进超高通量全基因组测序技术平台,提供从基因检测到健康全面解决方案，致力于倡导和引领预防医学，精准医疗事业，健康产业的发展，提升大众的健康生活品质，降低疾病风险。
云健康基因工厂
云健康生命中心
美国联络人:
Winston Patrick Kuo, DDS, DMSc
President Predicine,Inc.
650-300-2188 (USA) contact@predicine.cncontact@predicine.com
中国联络人：
金刚博士，总裁
云健康基因科技（上海）有限公司
云健康医疗科技集团
联系邮箱: Jason.Jin@cloudhealth99.com
Predicine and CloudHealth offer blood-based lung and prostate cancer tests in China
Chicago, IL – Predicine Inc and CloudHealth Genomics Ltd announced today at the American Society of Clinical Oncology(ASCO) 2016 meeting, to offer Predicine’s liquid biopsy tests to patients with lung (PrediSeq-Lung) or prostate (PrediSeq-Prostate) cancer in China.
Lung cancer is the number one cause ofmortality in China. Prostate cancer on the other hand is the fastest growing cancer type in China and the most common and second leading cause of cancer death in the western world. Earlier this year, Dr. Winston Patrick Kuo,President of Predicine, introduced their PrediSeq-Lung liquid biopsy test at the 23rd International Molecular Medicine Tri-Conference, which took place in San Francisco. A month later, Predicine presented data introducing PrediSeq-Prostate, world’s first liquid biospy NGS test for precision medicinein prostate cancer, at the American Association of Cancer Research (AACR) annual meeting in New Orleans. Both tests are based on Predicine’s patented NGS technology, detecting genetic alterations (mutations, copy number, indel, rearrangement and splice variants) in circulation.
"We are committed to developing the first- and best-in-classnon-invasive NGS-based cancer tests to enable personalized cancer care and global drug development,” said Dr. Shidong Jia, Founder and CEO of Predicine.“We are glad to work with industry leaders like CloudHealth so as to serve more patients in China in a timely manner,” Dr. Jia added. Predicine plans to launch additional tests for major cancer types in China later this year.
The tests have been rigorously validated and are now being adopted by lead ing pharmaceutical companies in the US and China. “The recognition of PrediSeq cancer tests by top-notch pharmaceutical companies is a testament of the science and quality behind Predicine,” Dr.Jason Jin, CEO and Co-founder of CloudHealth, said in a statement. “We are excited to move forward with Predicine to offer cancer patients and drug development companies instant access to the state-of-the-art liquid biopsy technology,” Dr. Jin added.
About Predicine
Predicine Holdings Ltd is an international precision medicine organization that is committed to developing innovative diagnostics, therapeutics and big data in cancer and other serious diseases. Predicine is formed by a group of industry veterans with leadership experience and domain expertise in precision oncology, liquid biopsy, cancer diagnostics, next-generation sequencing, biomarker development, drug discovery, clinicaltrial, bioinformatics and cloud computing. Following the principle of science-driven and patient-first spirit, Predicine develops innovative non-invasive precision diagnostic products in cancer and other serious diseases, provides an integrated "one-stop-shop" biomarker service platform, and conducts big data analyses to enable precision medicine in personalized cancer care and global drug development. The company operates in Hayward, California USA and Shanghai, China.Visit www.predicine.com to learn more.
About CloudHealth
CloudHealth is a high-techcompany, focusing on the transformation and application of precision medicalgenomics, is to be the leader of the China precision medical high-throughput sequencing and one of the advocates. By the National Development and Reform Commission, the first genetic testing demonstration center, The China Free Trade Zone International Precision Medical Cooperation Center.
CloudHealth established the world's most advanced high flux whole genome sequencing technology platform, providing comprehensive solution from genetic testing to health, is committed to advocacy and lead the preventive medicine, precision medical enterprise, the development of health industry, upgrade the quality of life ofthe public health, reduce the risk of disease.
Contact:
Company WinstonPatrick Kuo, DDS, DMSc
PresidentPredicine,Inc.
650-300-2188 (USA) contact@predicine.cncontact@predicine.com
Jason Gang Jin, MD, PhD
CEO, Co-Founder
CloudHealth Genomics Ltd.
Jason.Jin@cloudhealth99.com
点击下方“阅读原文”查看”雅虎财经“刊登原文报道
↓↓↓